WHO ICTRP trial
Phase 3 Open-Label Crossover Pharamacodynamic study to Evaluate the…
JPRN-jRCT2080222361 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080222361 |
|---|---|
| Public title | Phase 3 Open-Label Crossover Pharamacodynamic study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg with Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects |
| Scientific title | Phase 3 Open-Label Crossover Pharamacodynamic study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg with Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects |
| Primary sponsor | TAKEDA PHARMACEUTICAL COMPANY LTD. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Healthy Japanese adult male |
| Interventions | investigational material(s) Generic name etc : TAK-438 INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material : TAK-438 (20 mg) will be orally… |
| Registration date | Oct 1, 2014 |
| Target size | 40 |
| Secondary IDs | JapicCTI-142411 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: